Analysts expect SOPHiA GENETICS SA (NASDAQ:SOPH – Get Rating) to post sales of $10.76 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for SOPHiA GENETICS’s earnings. The lowest sales estimate is $10.68 million and the highest is $10.89 million. The firm is scheduled to announce its next quarterly earnings results before the market opens on Monday, January 1st.
On average, analysts expect that SOPHiA GENETICS will report full year sales of $52.45 million for the current year, with estimates ranging from $51.70 million to $52.86 million. For the next financial year, analysts forecast that the firm will report sales of $72.85 million, with estimates ranging from $69.20 million to $77.64 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover SOPHiA GENETICS.
SOPHiA GENETICS (NASDAQ:SOPH – Get Rating) last announced its quarterly earnings data on Tuesday, March 15th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.01. The firm had revenue of $10.94 million during the quarter, compared to analyst estimates of $11.27 million. SOPHiA GENETICS had a negative net margin of 182.14% and a negative return on equity of 39.82%.
Shares of SOPHiA GENETICS stock opened at $5.42 on Friday. The company has a 50 day moving average price of $8.11 and a 200 day moving average price of $11.55. SOPHiA GENETICS has a 52 week low of $5.34 and a 52 week high of $19.80.
A number of institutional investors and hedge funds have recently bought and sold shares of SOPH. Lombard Odier Asset Management Switzerland SA grew its stake in shares of SOPHiA GENETICS by 0.8% during the 4th quarter. Lombard Odier Asset Management Switzerland SA now owns 146,844 shares of the company’s stock worth $2,071,000 after purchasing an additional 1,174 shares during the period. Northern Trust Corp acquired a new stake in shares of SOPHiA GENETICS during the 4th quarter worth approximately $89,000. UBS Group AG acquired a new stake in shares of SOPHiA GENETICS during the 3rd quarter worth approximately $187,000. Moloney Securities Asset Management LLC grew its stake in shares of SOPHiA GENETICS by 39.0% during the 4th quarter. Moloney Securities Asset Management LLC now owns 40,650 shares of the company’s stock worth $573,000 after purchasing an additional 11,400 shares during the period. Finally, Geode Capital Management LLC acquired a new stake in shares of SOPHiA GENETICS during the 4th quarter worth approximately $189,000. 27.64% of the stock is owned by institutional investors.
About SOPHiA GENETICS (Get Rating)
SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide.
- Get a free copy of the StockNews.com research report on SOPHiA GENETICS (SOPH)
- Three Stocks To Ride Out A Rough Market
- MarketBeat: Week in Review 5/2 – 5/6
- AMD (NASDAQ: AMD) Shines Green In A Sea Of Red
- Expedia or Bookings Holdings: Which Stock Should You Travel With?
- Is This The Bottom For Papa John’s International?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.